Zerofos DS Tablet contains Calcium Acetate 1334 mg as its active ingredient and is primarily indicated for the management of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. Calcium Acetate acts as a phosphate binder by binding dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. This mechanism helps prevent complications associated with elevated phosphate levels, such as secondary hyperparathyroidism, vascular calcification, and renal osteodystrophy. Zerofos DS is administered orally, typically with meals, to maximize phosphate binding during digestion. The dosage should be individualized based on the patient’s serum phosphate levels and response to therapy. Common adverse effects may include hypercalcemia, gastrointestinal disturbances such as nausea, vomiting, constipation, or diarrhea. Regular monitoring of serum calcium, phosphate, and parathyroid hormone levels is essential to avoid complications and ensure therapeutic efficacy. Caution is advised in patients with hypercalcemia or those receiving calcium supplements or vitamin D analogs. Zerofos DS should be used under medical supervision, particularly in patients with impaired renal function, to optimize phosphate control and reduce the risk of morbidity associated with mineral and bone disorders in CKD.